Egyptian Drug Authority head Dr. Ali Al-Gamrawi has witnessed the signing of a partnership agreement between an Egyptian company and Chinese firm "Minhai" to transfer the technology for manufacturing the PCV-20 pneumococcal conjugate vaccine to Egypt. This move is expected to expand cooperation in vaccine production and localize the technology for high-priority vaccines. The agreement aims to enhance Egypt's capabilities in this field.
During his visit to China, Dr. Al-Gamrawi toured Minhai's facilities, inspecting the production line for the PCV-13 pneumococcal conjugate vaccine. He gained insight into the manufacturing process and the technical and technological capabilities employed in vaccine production. The visit also involved discussions on potential cooperation in technology transfer and exchanging technical expertise.
Dr. Al-Gamrawi emphasized the importance of expanding partnerships with specialized and leading vaccine manufacturers. He highlighted the benefits of leveraging advanced expertise and technology to support knowledge transfer, develop local manufacturing capabilities, and enhance the sustainability and competitiveness of Egypt's vaccine industry.
The talks also explored opportunities for cooperation in localizing vaccine manufacturing technology and developing production and technical capabilities. This cooperation is expected to support Egypt's local pharmaceutical industry, enhance drug security, and open up new avenues for collaboration with regional and international markets.
The visit to Minhai is part of the Egyptian Drug Authority's efforts to expand its international partnerships and strengthen cooperation with global vaccine manufacturers. The goal is to support technology transfer, localize manufacturing, and build national capacities, ultimately contributing to the development and increased competitiveness of Egypt's pharmaceutical industry.
By enhancing partnerships with leading international companies, Egypt aims to develop its pharmaceutical sector and improve its position in the global market. The agreement with Minhai marks a significant step towards achieving this goal, with potential benefits for Egypt's healthcare sector and economy.
The cooperation between Egypt and China is expected to have a positive impact on the development of Egypt's vaccine industry, enabling the country to produce high-quality vaccines and reduce its reliance on imports. This, in turn, will enhance the country's healthcare sector and contribute to its economic growth.
Key points
- The agreement between Egypt and China aims to transfer vaccine manufacturing technology to Egypt.
- The partnership agreement was signed between an Egyptian company and Chinese firm Minhai.
- The technology transfer is expected to enhance Egypt's capabilities in vaccine production and contribute to the development of its pharmaceutical industry.
